VIR Biotechnology, Inc.
San Francisco, CA VIR Biotechnology Inc.
- UEI
- VAGNEFK9N5X7
- CAGE
- 80UV6
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
VIR Biotechnology, Inc.
VAGNEFK9N5X7
- Tomegavax, Inc. NUE6Q16X2GL1
-
VIR Biotechnology, Inc.
VAGNEFK9N5X7
- SAM.gov registration date
- Physical address
- 1800 Owens St #900, San Francisco, CA 94158, USA
- Website
- vir.bio
- Founded
- 2016
- Employees
- 251-1K
- Estimated annual revenue
- $50M-$100M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| VIR biotechnology - OTA for pre-exposure prophylactic monoclonal antibodies for the prevention of influenza illness… | Office of the Assistant Secretary for Preparedness and Response | $65,867,804 |
About VIR Biotechnology, Inc.
VIR Biotechnology, Inc. is a commercial stage immunology company focused on combining immunologic insights with cutting edge technologies to treat and prevent serious infectious diseases. The company has assembled four technology platforms designed to stimulate and enhance the immune system by exploiting insights from antibody proteomics, T cell immunity, and innate immunity.
VIR Biotechnology, Inc. was awarded a $116.3 million definitive contract by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to support the development of pre-exposure prophylactic monoclonal antibodies for the prevention of influenza illness and medical countermeasures for other emerging pathogens with pandemic potential. The contract responds to the Office of Biomedical Advanced Research and Development Authority's broad agency announcement seeking proposals for the development of multiplexed SARS-CoV-2 antigen panel assay kits to measure antibodies against SARS-CoV-2 variants. VIR Biotechnology will function as the antigen panel assay kit developer and ISO 9001 manufacturer, with work taking place in San Francisco, California over a 10-year period ending in August 2032. No set aside designation was indicated.
VIR Biotechnology, Inc. has received two sub-grants from the federal government, both with the description "DELIVER STRUCTURE-ACTIVITY RELATIONSHIP CHEMISTRY ON A SERIES OF BROADLY ACTIVE AND ANTI-INFECTIVE COMPOUNDS AND IDENTIFY THEIR TARGETS." One of the sub-grants was awarded by The University Of Texas Southwestern Medical Center, which was likely the prime grantee organization.
Quick answers
What is VIR Biotechnology, Inc.'s UEI?
VIR Biotechnology, Inc.'s Unique Entity ID (UEI) in SAM.gov is VAGNEFK9N5X7.
What is VIR Biotechnology, Inc.'s CAGE code?
VIR Biotechnology, Inc.'s CAGE code is 80UV6.
What is VIR Biotechnology, Inc.'s primary NAICS code?
VIR Biotechnology, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is VIR Biotechnology, Inc. located?
VIR Biotechnology, Inc.'s physical address in SAM.gov is 1800 Owens St #900, San Francisco, CA 94158, USA.
Is VIR Biotechnology, Inc. registered in SAM.gov?
Yes. VIR Biotechnology, Inc.'s SAM.gov registration is active through September 9, 2027.
What is VIR Biotechnology, Inc.'s most recent federal award?
VIR Biotechnology, Inc.'s most recent federal contract award is VIR biotechnology - OTA for pre-exposure prophylactic monoclonal antibodies for the prevention of influenza illness… (75A50122C00081), from Office of the Assistant Secretary for Preparedness and Response, on September 30, 2022.
On GovTribe
See VIR Biotechnology, Inc.'s full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors